Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma

Virchows Archiv

Volumn 463, Issue 3, 2013, Pages 427-436

  Sun, Ping Li ^a   Jin, Yan ^a   Kim, Hyojin ^a   Seo, An Na ^a   Jheon, Sanghoon ^a   Lee, Choon Taek ^a   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Apoptosis; Non small cell lung cancer; Prognosis; Survivin

Indexed keywords

SURVIVIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR INVASION; VASCULAR TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INCIDENCE; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884133225     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1462-9     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-1380. doi: 10.1056/NEJMra0802714
3. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet 378(9804):1727-1740. doi: 10.1016/S0140-6736(10)62101-0
4. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11(11):3974-3986. doi: 10.1158/1078-0432.CCR-04-2661
5. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF (2003) Apoptosis and lung cancer: a review. J Cell Biochem 88(5):885-898. doi: 10.1002/jcb.10440
6. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244(2):164-171. doi: 10.1016/j.canlet.2006.03.007
7. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917-921. doi: 10.1038/nm0897-917
8. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R (2012) Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 7(3):e34100. doi: 10.1371/journal.pone.0034100
9. Hinnis AR, Luckett JC, Walker RA (2007) Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96(4):639-645. doi: 10.1038/sj.bjc.6603616
10. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E (2003) Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 120(5):712-719. doi: 10.1309/GWTN-2JTA-N6K7-3YDE
11. Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C (2006) Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 449(2):164-170. doi: 10.1007/s00428-006-0239-9
12. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G, Bosari S (2003) Survivin gene expression in early stage non-small cell lung cancer. J Pathol 200(5):620-626. doi: 10.1002/path.1388
13. Leist M, Jaattela M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2(8):589-598. doi: 10.1038/35085008
14. Fan J, Wang L, Jiang GN, He WX, Ding JA (2008) The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 61(1):91-96. doi: 10.1016/j.lungcan.2007.11.011
15. Shinohara ET, Hallahan DE, Lu B (2004) The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biol Proced Online 6:250-256. doi: 10.1251/bpo95
16. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH (2013) Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev. doi: 10.1016/j.ctrv.2013.02.002
17. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26(32):5198-5203. doi: 10.1200/JCO.2008.17.2064
18. Atikcan S, Unsal E, Demirag F, Koksal D, Yilmaz A (2006) Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med 100(12):2220-2226. doi: 10.1016/j.rmed.2006.02.031
19. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R (2012) A novel classification of lung cancer into molecular subtypes. PLoS One 7(2):e31906. doi: 10.1371/journal.pone.0031906
20. Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 70(24):10402-10410. doi: 10.1158/0008-5472.CAN-10-2438
21. Takezawa K, Okamoto I, Nishio K, Janne PA, Nakagawa K (2011) Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 17(8):2140-2148. doi: 10.1158/1078-0432.CCR-10-2798
22. Zhu CQ, Shih W, Ling CH, Tsao MS (2006) Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59(8):790-800. doi: 10.1136/jcp.2005.031351
23. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH (2012) High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7(2):323-330. doi: 10.1097/JTO.0b013e3182381515
24. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6(8):1359-1366. doi: 10.1097/JTO.0b013e31821cfc73
25. Huang LN, Wang DS, Chen YQ, Zhao CL, Gong BL, Jiang AB, Jia W, Hu FD (2013) Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. Mol Biol Rep 40(2):917-924. doi: 10.1007/s11033-012-2132-8
26. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G (2004) Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 15(11):1654-1660. doi: 10.1093/annonc/mdh436
27. Rosato A, Menin C, Boldrin D, Santa SD, Bonaldi L, Scaini MC, Del Bianco P, Zardo D, Fassan M, Cappellesso R, Fassina A (2013) Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer 79(2):180-186. doi: 10.1016/j.lungcan.2012.11.004
28. McDoniels-Silvers AL, Stoner GD, Lubet RA, You M (2002) Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 4(2):141-150. doi: 10.1097/01.pai.0000201808.35931.78
29. Perez-Moreno P, Brambilla E, Thomas R, Soria JC (2012) Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 18(9):2443-2451. doi: 10.1158/1078-0432.CCR-11-2370